Literature DB >> 17965487

Increased incidence of coronary in-stent restenosis in type 2 diabetic patients is related to elevated serum malondialdehyde-modified low-density lipoprotein.

Sakuji Shigematsu1, Naohiko Takahashi, Masahide Hara, Hironobu Yoshimatsu, Tetsunori Saikawa.   

Abstract

BACKGROUND: Type 2 diabetes mellitus (T2DM) has been reported as a major risk factor for in-stent restenosis (ISR) after intracoronary stenting, although the details of the mechanisms remain undefined. The aim of present study was to investigate the diabetes-related risk factor for ISR. METHODS AND
RESULTS: A total of 131 patients who were implanted with bare metal stent(s) were enrolled in this study. Based on follow-up coronary angiography at 6 months after stenting, the patients were classified according to the presence or absence of ISR. Various coronary risk factors, including serum malondialdehyde-modified low-density lipoprotein (MDA-LDL) levels, were investigated at follow-up angiogram to relate to ISR in patients with or without T2DM. The increased incidence of ISR was observed in diabetic patients, which was significantly related to the increased serum MDA-LDL concentrations. The serum MDA-LDL concentration was positively correlated to glycohemoglobin levels in diabetic patients. In addition, MDA-LDL concentration was not altered after the treatment of ISR.
CONCLUSIONS: The elevated serum MDA-LDL level is considered to be a potent risk factor for ISR in diabetic patients. MDA-LDL, which might be a consequence of metabolic abnormalities caused by diabetes, may act as a growth factor for neointimal tissues inside the implanted stent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17965487     DOI: 10.1253/circj.71.1697

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  7 in total

1.  Advanced Glycation End Products:Receptors for Advanced Glycation End Products Axis in Coronary Stent Restenosis: A Prospective Study.

Authors:  Colin Pearce; Naorin Islam; Robyn Bryce; Erick Donnell McNair
Journal:  Int J Angiol       Date:  2018-10-29

2.  Increase in the oxidised low-density lipoprotein level by smoking and the possible inhibitory effect of statin therapy in patients with cardiovascular disease: a retrospective study.

Authors:  Kazuo Ogawa; Toshikazu Tanaka; Tomohisa Nagoshi; Hiroshi Sekiyama; Satoshi Arase; Kosuke Minai; Takayuki Ogawa; Michihiro Yoshimura
Journal:  BMJ Open       Date:  2015-01-21       Impact factor: 2.692

3.  Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease.

Authors:  Morihiro Matsuda; Ritsu Tamura; Kotaro Kanno; Takatsugu Segawa; Haruyuki Kinoshita; Orie Nishimoto; Hirohiko Nishiyama; Toshiharu Kawamoto
Journal:  Diabetol Metab Syndr       Date:  2013-12-06       Impact factor: 3.320

4.  Effect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patients.

Authors:  Masami Tanaka; Risa Nishimura; Takeshi Nishimura; Toshihide Kawai; Shu Meguro; Junichiro Irie; Yoshifumi Saisho; Hiroshi Itoh
Journal:  Diabetol Metab Syndr       Date:  2014-05-18       Impact factor: 3.320

5.  Parallel comparison of risk factors between progression of organic stenosis in the coronary arteries and onset of acute coronary syndrome by covariance structure analysis.

Authors:  Kazuo Ogawa; Kosuke Minai; Makoto Kawai; Toshikazu Tanaka; Tomohisa Nagoshi; Takayuki Ogawa; Michihiro Yoshimura
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

6.  [Not Available].

Authors:  Ahmed A Alsaddique
Journal:  Open Cardiovasc Med J       Date:  2009-04-30

7.  A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol.

Authors:  Xiao-Wei Ma; Xiao-Hui Guo; Xin-Hua Xiao; Li-Xin Guo; Xiao-Feng Lv; Quan-Min Li; Yan Gao
Journal:  J Geriatr Cardiol       Date:  2012-09       Impact factor: 3.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.